FDA Releases Draft Guidance on Reducing Risk of Creutzfeldt-Jakob Disease Transmission through Blood Products

Summary

The Food and Drug Administration (FDA) has made available a draft document outlining revised preventive measures to minimize the risk of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) transmission through blood and blood products, with the goal of protecting public health.